Stock Events

Stock Events

Verrica Pharmaceuticals 

$3.30
0
-$0.28-7.82%Thursday 08:24

Statistics

Day High
3.65
Day Low
3.23
52W High
8.43
52W Low
3.04
Volume
18,533
Avg. Volume
-
Mkt Cap
56.69M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 9Expected
Q3 2025
Q1 2026
Q2 2026
Next
-0.62
-0.42
-0.23
-0.03
Expected EPS
-0.49742
Actual EPS
N/A

Financials

-50.27%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
35.58MRevenue
-17.89MNet Income

Analyst Ratings

$12.00Average Price Target
The highest estimate is ⁦12.00⁩.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow VRCA.BOATS. It's not an investment recommendation.
AMD
6
AMD
Apple
5
AAPL
Realty Income
4
O
Amazon
4
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AnaptysBio
ANAB
Mkt Cap1.44B
AnaptysBio, Inc. focuses on developing antibody-based therapies for dermatological conditions, directly competing with Verrica's dermatology products.
Journey Medical
DERM
Mkt Cap145.92M
Journey Medical Corporation is directly involved in dermatology, marketing products that compete in the same space as Verrica's treatments for skin conditions.
Bausch Health Companies
BHC
Mkt Cap3.07B
Bausch Health Companies Inc. has a broad portfolio in dermatology, offering products that compete with Verrica's skin treatment solutions.
Pfizer
PFE
Mkt Cap167.52B
Pfizer Inc. has a diverse range of healthcare products, including treatments for dermatological conditions, making it a competitor in the dermatology market.
Johnson & Johnson
JNJ
Mkt Cap664.95B
Johnson & Johnson, through its Janssen Pharmaceuticals segment, offers products for skin health, competing in the same market as Verrica.
Abbvie
ABBV
Mkt Cap514.92B
AbbVie Inc. has a strong presence in dermatology with its Humira product and others, competing in the same therapeutic areas as Verrica.
AMGEN
AMGN
Mkt Cap249.05B
Amgen Inc. develops treatments for various conditions, including skin diseases, making it a competitor in the dermatology space.
GSK
GSK
Mkt Cap100.88B
GlaxoSmithKline plc has a portfolio that includes treatments for skin conditions, competing with Verrica's dermatological products.
Merck
MRK
Mkt Cap361.73B
Merck & Co., Inc. offers a range of healthcare products, including treatments for skin conditions, making it a competitor in the dermatology market.
Regeneron Pharmaceuticals
REGN
Mkt Cap95.99B
Regeneron Pharmaceuticals, Inc. is known for its innovative treatments in dermatology, directly competing with Verrica Pharmaceuticals in the development of skin disease treatments.

About

Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.
Show More
CEO
ISIN
US92511W2070

Listings

XNAS
US
VRCA
STU
DE
1NE0.STU
STU
DE
1NE.STU
MU
DE
1NE0.MU

0 Comments

Share your thoughts

FAQs

What is Verrica Pharmaceuticals stock price today?▼
The current price of VRCA.BOATS is $3.30 USD — it has decreased by -7.82% in the past 24 hours. Watch Verrica Pharmaceuticals stock price performance more closely on the chart.
What is Verrica Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boats exchange Verrica Pharmaceuticals stocks are traded under the ticker VRCA.BOATS.
What is Verrica Pharmaceuticals market cap?▼
Today Verrica Pharmaceuticals has the market capitalization of 56.69M
What is Verrica Pharmaceuticals revenue for the last year?▼
Verrica Pharmaceuticals revenue for the last year amounts to 35.58M USD.
What is Verrica Pharmaceuticals net income for the last year?▼
VRCA.BOATS net income for the last year is -17.89M USD.
In which sector is Verrica Pharmaceuticals located?▼
Verrica Pharmaceuticals operates in the Other sector.
When did Verrica Pharmaceuticals complete a stock split?▼
The last stock split for Verrica Pharmaceuticals was on July 25, 2025 with a ratio of 1:10.